candesartan cilexetil has been researched along with pevonedistat in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, X; Hu, Z; Huang, J; Jia, L; Li, B; Li, J; Mao, F; Ni, S; Sun, Y; Xu, Y; Yang, X; Yu, Q; Zhang, J; Zhang, W | 1 |
| Chen, X; Jia, L; Li, B; Li, J; Mao, F; Ni, S; Wei, J; Xu, Y; Yang, X; Zhu, J | 1 |
2 other study(ies) available for candesartan cilexetil and pevonedistat
| Article | Year |
|---|---|
Discovery of candesartan cilexetic as a novel neddylation inhibitor for suppressing tumor growth.
Topics: A549 Cells; Animals; Antineoplastic Agents; Benzimidazoles; Biphenyl Compounds; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Discovery; Drug Screening Assays, Antitumor; Female; Humans; Injections, Intraperitoneal; Injections, Subcutaneous; Mice; Mice, Nude; Molecular Structure; Neoplasms, Experimental; Structure-Activity Relationship; Tetrazoles | 2020 |
Development of novel benzimidazole-derived neddylation inhibitors for suppressing tumor growth invitro and invivo.
Topics: A549 Cells; Animals; Antineoplastic Agents; Benzimidazoles; Cell Proliferation; Female; Humans; Lung Neoplasms; Mice, Nude; Models, Molecular; Ubiquitin-Activating Enzymes | 2021 |